Source:http://linkedlifedata.com/resource/pubmed/id/17917963
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2007-10-5
|
| pubmed:abstractText |
We designed intermediate dose etoposide + G-CSF 16 microg/kg as a Peripheral Blood Stem Cell (PBSC) mobilization schedule suitable for outpatient administration. Forty-one Lymphoma patients received intermediate dose etoposide (200 mg/m(2) i.v. day +1, +2, +3) +G-CSF 16 microg/kg/day. Results of PBSC mobilization in these patients were compared with those of a group of 37 lymphoma patients mobilized using cyclophosphamide (CTX) at dosage of 4 g/m(2) + G-CSF 10 microg/kg/die. Mean peak of CD34+ cells achieved in P.B. and total CD34+ cells harvested were higher in patients mobilized with intermediate dose etoposide (p = 0.003 and p = 0.004, respectively). After transplantation recovery of polymorphonucleate neutrophils (PMN) > 0.5 x 10(9)/L did not differ significantly between groups: 11.7 days in intermediate dose etoposide group and 11.5 days in CTX group (p = 0.7). Intermediate dose etoposide + G-CSF 16 microg/kg resulted in a maximum length of neutropenia (PMN < 0.5 x 10(9)/L) of 2 days and neutropenic fever was registered during only 3/41 courses (7.3%). Intermediate dose etoposide + G-CSF 16 microg/kg is a highly effective mobilizing therapy, further, it has the advantage of low hematologic toxicity and can be easily administered as outpatient treatment.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1042-8194
|
| pubmed:author |
pubmed-author:AvolaGiuseppeG,
pubmed-author:BattiatoKatiaK,
pubmed-author:CamugliaMaria GraziaMG,
pubmed-author:CoppolettaStefaniaS,
pubmed-author:GiustolisiRosarioR,
pubmed-author:LeottaSalvatoreS,
pubmed-author:MauroElisaE,
pubmed-author:MercurioSalvatoreS,
pubmed-author:MiloneGiuseppeG,
pubmed-author:MurganoPamelaP,
pubmed-author:PintoValeriaV,
pubmed-author:PoidomaniMassimoM,
pubmed-author:StranoAuroraA
|
| pubmed:issnType |
Print
|
| pubmed:volume |
48
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1950-60
|
| pubmed:meshHeading |
pubmed-meshheading:17917963-Adolescent,
pubmed-meshheading:17917963-Adult,
pubmed-meshheading:17917963-Aged,
pubmed-meshheading:17917963-Cyclophosphamide,
pubmed-meshheading:17917963-Drug Therapy, Combination,
pubmed-meshheading:17917963-Etoposide,
pubmed-meshheading:17917963-Female,
pubmed-meshheading:17917963-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:17917963-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:17917963-Humans,
pubmed-meshheading:17917963-Immunosuppressive Agents,
pubmed-meshheading:17917963-Leukapheresis,
pubmed-meshheading:17917963-Lymphoma,
pubmed-meshheading:17917963-Male,
pubmed-meshheading:17917963-Middle Aged,
pubmed-meshheading:17917963-Outpatients,
pubmed-meshheading:17917963-Stem Cell Transplantation,
pubmed-meshheading:17917963-Stem Cells,
pubmed-meshheading:17917963-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients.
|
| pubmed:affiliation |
Divisione Clinicizzata di Ematologia e Unità di Trapianto di Midollo Osseo, Catania, Italy. guwgim@tin.it
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|